About us

ChemomAb specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. Read More


Research & Development

ChemomAb identified a novel chemokine pathway that mediates inflammation and fibrosis and developed proprietary antibodies that target it. Compelling data has been gathered on the efficacy of our lead compound in the orphan disease. Read More



ChemomAb orally presented in the Systemic Sclerosis World Congress. The presentation was about CM-101, our lead agent and its activity in blocking CCL24 Ameliorates experimental SSC and IPF and A Novel antibody blocking  CCL24/CCR3 in SSC. Read More